Skip to main content
Erschienen in: Digestive Diseases and Sciences 8/2021

14.09.2020 | Original Article

Femoral Vein Wall Thickness Measurement May Be a Distinctive Diagnostic Tool to Differentiate Behçet’s Disease with Intestinal Involvement and Crohn’s Disease

verfasst von: Fatma Alibaz-Oner, Rabia Ergelen, Ilkay Ergenc, Gizem Seven, Ayten Yazıcı, Ayse Cefle, Cemal Bes, Ozlen Atug, Haner Direskeneli

Erschienen in: Digestive Diseases and Sciences | Ausgabe 8/2021

Einloggen, um Zugang zu erhalten

Abstract

Backgrounds

Behçet’s disease (BD) and Crohn’s disease (CD) cannot be easily differentiated in young adults presenting with nonspecific gastrointestinal (GI) manifestations due to similar extraintestinal manifestations. We recently showed that increased common femoral vein (CFV) thickness is a distinctive feature of BD, rarely present in other inflammatory or vascular diseases with a specificity higher than 80% for the cutoff value of ≥ 0.5 mm. We suggest that CFV thickness measurement with ultrasonography (US) can be a diagnostic tool for BD.

Aims

To assess the diagnostic performance of CFV thickness measurement in the differential diagnosis of BD and CD.

Methods

Patients with BD (n = 69), CD (n = 38), and healthy controls (HC) (n = 38) were included in the study. Bilateral CFV thickness was measured with Doppler US.

Results

Both right and left CFV thicknesses were significantly higher in BD compared to HC and CD (for right: 0.76 mm vs 0.33 mm, for left: 0.78 mm vs 0.35 mm, p < 0.001 for both). CFV thicknesses in CD were similar to HC (p > 0.05 for both). CFV thickness was also similar between BD patients with and without GI involvement (p = 0.367). The diagnostic cutoff values of ≥ 0.5 mm for CFV thickness performed well against to both CD and HCs for discrimination of BD. The sensitivity and specificity rates were > 85% for both HC and CD. Positive and negative predictive values in our tertiary clinical setting were > 90%.

Conclusion

We found significantly lower CFV thickness in CD compared to BD. Our results suggest that CFV wall thickness measurement is a distinctive diagnostic tool for the differentiation of BD and CD and can be helpful in daily practice for the differentiation of two diseases.
Literatur
1.
Zurück zum Zitat Yazici H, Yurdakul S, Hamuryudan V. Behcçet disease. Curr Opin Rheumatol. 2001;13:18–22.CrossRef Yazici H, Yurdakul S, Hamuryudan V. Behcçet disease. Curr Opin Rheumatol. 2001;13:18–22.CrossRef
2.
Zurück zum Zitat Shimizu T, Ehrlich GE, Inaba G, Hayashi K. Behçet’s disease (Behçet syndrome). Semin Arthritis Rheum. 1979;8:223–260.CrossRef Shimizu T, Ehrlich GE, Inaba G, Hayashi K. Behçet’s disease (Behçet syndrome). Semin Arthritis Rheum. 1979;8:223–260.CrossRef
3.
Zurück zum Zitat Kim DK, Yang SK, Byeon JS, et al. Clinical manifestations and course of intestinal Behçet’s disease: an analysis in relation to disease subtypes. Intest Res. 2005;3:48–54. Kim DK, Yang SK, Byeon JS, et al. Clinical manifestations and course of intestinal Behçet’s disease: an analysis in relation to disease subtypes. Intest Res. 2005;3:48–54.
4.
Zurück zum Zitat Maaser C, Maaser C, Sturm A, et al. ECCO-ESGAR guideline for diagnostic assessment in IBD Part 1: initial diagnosis, monitoring of known IBD, detection of complications. J Crohn’s Colitis. 2019;13:144–164.CrossRef Maaser C, Maaser C, Sturm A, et al. ECCO-ESGAR guideline for diagnostic assessment in IBD Part 1: initial diagnosis, monitoring of known IBD, detection of complications. J Crohn’s Colitis. 2019;13:144–164.CrossRef
5.
Zurück zum Zitat Kim DH, Cheon JH. Intestinal Behcet’s disease: a true inflammatory bowel disease or merely an intestinal complication of systemic vasculitis? Yonsei Med J. 2016;57:22–32.CrossRef Kim DH, Cheon JH. Intestinal Behcet’s disease: a true inflammatory bowel disease or merely an intestinal complication of systemic vasculitis? Yonsei Med J. 2016;57:22–32.CrossRef
6.
Zurück zum Zitat Yim CW, White RH. Behçet’s syndrome in a family with inflammatory bowel disease. Arch Intern Med. 1985;145:1047–1050.CrossRef Yim CW, White RH. Behçet’s syndrome in a family with inflammatory bowel disease. Arch Intern Med. 1985;145:1047–1050.CrossRef
7.
Zurück zum Zitat Hatemi I, Esatoglu SN, Hatemi G, et al. Characteristics, treatment, and long-term outcome of gastrointestinal involvement in Behcet’s Syndrome: a strobe-compliant observational study from a dedicated multidisciplinary center. Medicine (Baltimore). 2016;95:e3348.CrossRef Hatemi I, Esatoglu SN, Hatemi G, et al. Characteristics, treatment, and long-term outcome of gastrointestinal involvement in Behcet’s Syndrome: a strobe-compliant observational study from a dedicated multidisciplinary center. Medicine (Baltimore). 2016;95:e3348.CrossRef
8.
Zurück zum Zitat Jung YS, Cheon JH, Park SJ, et al. Long-term clinical outcomes of Crohn’s disease and intestinal Behcet’s disease. Inflamm Bowel Dis. 2013;19:99–105.CrossRef Jung YS, Cheon JH, Park SJ, et al. Long-term clinical outcomes of Crohn’s disease and intestinal Behcet’s disease. Inflamm Bowel Dis. 2013;19:99–105.CrossRef
9.
Zurück zum Zitat Zhang T, Hong L, Wang Z, et al. Comparison between intestinal Behcet’s disease and Crohn’s disease in characteristics of symptom, endoscopy, and radiology. Gastroenterol Res Pract. 2017;2017:3918746.PubMedPubMedCentral Zhang T, Hong L, Wang Z, et al. Comparison between intestinal Behcet’s disease and Crohn’s disease in characteristics of symptom, endoscopy, and radiology. Gastroenterol Res Pract. 2017;2017:3918746.PubMedPubMedCentral
10.
Zurück zum Zitat Levine JS, Burakoff R. Extraintestinal manifestations of inflammatory bowel disease. Gastroenterol Hepatol. 2011;7:235. Levine JS, Burakoff R. Extraintestinal manifestations of inflammatory bowel disease. Gastroenterol Hepatol. 2011;7:235.
11.
Zurück zum Zitat Alibaz-Oner F, Mutis A, Ergelen R, et al. Venous vessel wall thickness in lower extremity is increased in male Behcet’s disease patients without vascular involvement. Rheumatology. 2017;56:ii91–iii92.CrossRef Alibaz-Oner F, Mutis A, Ergelen R, et al. Venous vessel wall thickness in lower extremity is increased in male Behcet’s disease patients without vascular involvement. Rheumatology. 2017;56:ii91–iii92.CrossRef
12.
Zurück zum Zitat Alibaz-Oner F, Ergelen R, Mutis A, et al. Venous vessel wall thickness in lower extremity is increased in male patients with Behçet’s disease. Clin Rheumatol. 2019;38:1447–1451.CrossRef Alibaz-Oner F, Ergelen R, Mutis A, et al. Venous vessel wall thickness in lower extremity is increased in male patients with Behçet’s disease. Clin Rheumatol. 2019;38:1447–1451.CrossRef
14.
Zurück zum Zitat International Study Group for Behçet’s Disease. Criteria for diagnosis of Behçet’s disease. Lancet. 1990;335:1078–1080. International Study Group for Behçet’s Disease. Criteria for diagnosis of Behçet’s disease. Lancet. 1990;335:1078–1080.
15.
Zurück zum Zitat Maaser C, Sturm A, Vavricka SR, et al. European Crohn’s and Colitis Organisation [ECCO] and the European Society of Gastrointestinal and Abdominal Radiology [ESGAR]. ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: initial diagnosis, monitoring of known IBD, detection of complications. J Crohns Colitis. 2019;13:144–164.CrossRef Maaser C, Sturm A, Vavricka SR, et al. European Crohn’s and Colitis Organisation [ECCO] and the European Society of Gastrointestinal and Abdominal Radiology [ESGAR]. ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: initial diagnosis, monitoring of known IBD, detection of complications. J Crohns Colitis. 2019;13:144–164.CrossRef
16.
Zurück zum Zitat Yilmaz S, Simsek I, Cinar M, et al. Patient driven assessment of disease activity in Behçet’s syndrome: cross-cultural adaptation, reliability and validity of the Turkish version of the Behçet’s Syndrome Activity Score. Clin Exp Rheumatol. 2013;31:77–83.PubMed Yilmaz S, Simsek I, Cinar M, et al. Patient driven assessment of disease activity in Behçet’s syndrome: cross-cultural adaptation, reliability and validity of the Turkish version of the Behçet’s Syndrome Activity Score. Clin Exp Rheumatol. 2013;31:77–83.PubMed
17.
Zurück zum Zitat Best WR, Becktel JM, Singleton JW, Kern F. Development of a Crohn’s disease activity index: National Cooperative Crohn’s Disease Study. Gastroenterology. 1976;70:439–444.CrossRef Best WR, Becktel JM, Singleton JW, Kern F. Development of a Crohn’s disease activity index: National Cooperative Crohn’s Disease Study. Gastroenterology. 1976;70:439–444.CrossRef
18.
Zurück zum Zitat Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55:749–753.CrossRef Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55:749–753.CrossRef
19.
Zurück zum Zitat Cheon JH, Hatemi I, Çelik AF. Behçet syndrome: gastrointestinal involvement. In: Yazici Y, et al., eds. Behçet Syndrome. 2nd ed. Switzerland: Springer; 2020:83–103. Cheon JH, Hatemi I, Çelik AF. Behçet syndrome: gastrointestinal involvement. In: Yazici Y, et al., eds. Behçet Syndrome. 2nd ed. Switzerland: Springer; 2020:83–103.
20.
Zurück zum Zitat Lee HJ, Cheon JH. Optimal diagnosis and disease activity monitoring of intestinal Behçet’s disease. Intestinal Res. 2017;15:311.CrossRef Lee HJ, Cheon JH. Optimal diagnosis and disease activity monitoring of intestinal Behçet’s disease. Intestinal Res. 2017;15:311.CrossRef
21.
Zurück zum Zitat Hatemi I, Hatemi G, Celik AF, et al. Frequency of pathergy phenomenon and other features of Behc¸ et’s syndrome among patients with inflammatory bowel disease. Clin Exp Rheumatol. 2008;26:S91–S95.PubMed Hatemi I, Hatemi G, Celik AF, et al. Frequency of pathergy phenomenon and other features of Behc¸ et’s syndrome among patients with inflammatory bowel disease. Clin Exp Rheumatol. 2008;26:S91–S95.PubMed
22.
Zurück zum Zitat Jung HC, Rhee PL, Song IS, et al. Temporal changes in the clinical type or diagnosis of Behcet’s colitis in patients with aphthoid or punched-out colonic ulcerations. J Korean Med Sci. 1991;6:313–318.CrossRef Jung HC, Rhee PL, Song IS, et al. Temporal changes in the clinical type or diagnosis of Behcet’s colitis in patients with aphthoid or punched-out colonic ulcerations. J Korean Med Sci. 1991;6:313–318.CrossRef
23.
Zurück zum Zitat Lee SK, Kim BK, Kim TI, Kim WH. Differential diagnosis of intestinal Behçet’s Disease and Crohn’s disease by colonoscopic findings. Endoscopy. 2009;41:9–16.CrossRef Lee SK, Kim BK, Kim TI, Kim WH. Differential diagnosis of intestinal Behçet’s Disease and Crohn’s disease by colonoscopic findings. Endoscopy. 2009;41:9–16.CrossRef
24.
Zurück zum Zitat Cheon JH, Kim ES, Shin SJ, et al. Development and validation of novel diagnostic criteria for intestinal Behcet’s disease in Korean patients with ileocolonic ulcers. Am J Gastroenterol. 2009;104:2492–2499.CrossRef Cheon JH, Kim ES, Shin SJ, et al. Development and validation of novel diagnostic criteria for intestinal Behcet’s disease in Korean patients with ileocolonic ulcers. Am J Gastroenterol. 2009;104:2492–2499.CrossRef
25.
Zurück zum Zitat Shin SJ, Lee SK, Kim TI, et al. Chronological changes in the systemic manifestations of intestinal Behcet’s disease and their significance in diagnosis. Int J Colorectal Dis. 2010;25:1371–1376.CrossRef Shin SJ, Lee SK, Kim TI, et al. Chronological changes in the systemic manifestations of intestinal Behcet’s disease and their significance in diagnosis. Int J Colorectal Dis. 2010;25:1371–1376.CrossRef
26.
Zurück zum Zitat Fresko I, Ugurlu U, Ozbakir F, et al. Anti-Saccharomyces Cerevisiae Antibodies (ASCA) in Behçet’s Syndrome. Clin Exp Rheumatol. 2005;23:S67–S70.PubMed Fresko I, Ugurlu U, Ozbakir F, et al. Anti-Saccharomyces Cerevisiae Antibodies (ASCA) in Behçet’s Syndrome. Clin Exp Rheumatol. 2005;23:S67–S70.PubMed
27.
Zurück zum Zitat Esatoglu SN, Hatemi I, Ozguler Y, et al. Faecal but not serum calprotectin levels look promising in predicting active disease in Behçet’s syndrome patients with gastrointestinal involvement. Clin Exp Rheumatol. 2018;36:90–96. Epub. 12/13/2018.PubMed Esatoglu SN, Hatemi I, Ozguler Y, et al. Faecal but not serum calprotectin levels look promising in predicting active disease in Behçet’s syndrome patients with gastrointestinal involvement. Clin Exp Rheumatol. 2018;36:90–96. Epub. 12/13/2018.PubMed
28.
Zurück zum Zitat Quinton JF, Sendid B, Reumaux D, et al. Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic auto-antibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut. 1998;42:788–791.CrossRef Quinton JF, Sendid B, Reumaux D, et al. Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic auto-antibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut. 1998;42:788–791.CrossRef
29.
Zurück zum Zitat Kristensen VA, Cvancarova M, Høivik ML, Moum B, Vatn MH. Serological antibodies and surgery in a population-based inception cohort of Crohn’s disease patients—the IBSEN study. Scand J Gastroenterol. 2020;55:436–441.CrossRef Kristensen VA, Cvancarova M, Høivik ML, Moum B, Vatn MH. Serological antibodies and surgery in a population-based inception cohort of Crohn’s disease patients—the IBSEN study. Scand J Gastroenterol. 2020;55:436–441.CrossRef
30.
Zurück zum Zitat Geboes K. What histologic features best differentiate Crohn’s disease from ulcerative colitis? Inflamm Bowel Dis. 2008;14:S168–S169.CrossRef Geboes K. What histologic features best differentiate Crohn’s disease from ulcerative colitis? Inflamm Bowel Dis. 2008;14:S168–S169.CrossRef
31.
Zurück zum Zitat Alibaz-Oner F, Karadeniz A, Yılmaz S, et al. Behçet disease with vascular involvement: effects of different therapeutic regimens on the incidence of new relapses. Medicine (Baltimore). 2015;94:e494.CrossRef Alibaz-Oner F, Karadeniz A, Yılmaz S, et al. Behçet disease with vascular involvement: effects of different therapeutic regimens on the incidence of new relapses. Medicine (Baltimore). 2015;94:e494.CrossRef
32.
Zurück zum Zitat Nguyen GC, Bernstein CN, Bitton A, et al. Consensus statements on the risk, prevention, and treatment of venous thromboembolism in inflammatory bowel disease: Canadian Association of Gastroenterology. Gastroenterology. 2014;146:835–848.e6.CrossRef Nguyen GC, Bernstein CN, Bitton A, et al. Consensus statements on the risk, prevention, and treatment of venous thromboembolism in inflammatory bowel disease: Canadian Association of Gastroenterology. Gastroenterology. 2014;146:835–848.e6.CrossRef
Metadaten
Titel
Femoral Vein Wall Thickness Measurement May Be a Distinctive Diagnostic Tool to Differentiate Behçet’s Disease with Intestinal Involvement and Crohn’s Disease
verfasst von
Fatma Alibaz-Oner
Rabia Ergelen
Ilkay Ergenc
Gizem Seven
Ayten Yazıcı
Ayse Cefle
Cemal Bes
Ozlen Atug
Haner Direskeneli
Publikationsdatum
14.09.2020
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 8/2021
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-020-06587-7

Weitere Artikel der Ausgabe 8/2021

Digestive Diseases and Sciences 8/2021 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.